Nearly a third of the participants ... study on the side-effects of Bharat Biotech's Covid-19 vaccine Covaxin reported adverse events of special interest (AESI), according to a report on ...
Nearly a third of the participants ... study on the side-effects of Bharat Biotech's Covid-19 vaccine Covaxin reported adverse events of special interest (AESI), according to the report.
Covaxin, the Covid-19 vaccine ... The participants of the study, which involved 635 adolescents and 291 adults, were interviewed telephonically about long-term adverse events of special interest ...
Adolescent girls and those with comorbidities are at a higher risk of adverse events after receiving Bharat Biotech’s BBV152 (Covaxin) vaccine against COVID-19, according to a report published ...
Nearly one-third of 926 individuals who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI, according to a one-year follow up study ...
Nearly one-third of Covaxin recipients experienced adverse events of special ... abnormalities, the study claims, were noticed in 5% of women who took Covaxin, the Covid-19 vaccine developed ...
New Delhi: Close to one-third of over 900 individuals receiving Covaxin shots have developed some ... made Covid-19 vaccine, Indian scientists have reported. The study on the long term adverse ...
A recent study ... Biotech's Covaxin reported adverse events. The one-year follow-up study, encompassing 926 participants, shed light on the long-term safety of the BBV152 vaccine, with serious ...
An observational study on Bharat Biotech's Covaxin ... participants experienced adverse events. This follows recent admissions by AstraZeneca regarding side effects from its own COVID-19 vaccine.
The study involved 635 adolescents and 291 adults, who received the BBV152 vaccine. The participants were interviewed telephonically about long-term adverse events ... COVID-19 was present in ...
Covaxin: an inactivated virus vaccine, was one of the first Covid-19 vaccines developed ... term follow-up of all study participants to capture late-onset adverse events. The debate over ...